JPM25: AbbVie pens $1B deal for Simcere’s phase 1 T-cell engager

T-cell engagers have been hot property in recent months, so it’s only right that one the biggest deals to kick off the J.P. Morgan Healthcare conference should see AbbVie expanding its interest in the tech.

The Big Pharma is handing China’s Simcere Zaiming an undisclosed upfront payment with the potential of up to $1.05 billion in milestone payments for a phase 1-stage trispecific antibody. The candidate, dubbed SIM0500, targets GPRC5D, BCMA and CD3 and is already in phase 1 trials for multiple myeloma in the U.S. and China.